Our Story and Vision:
Advancing Psychedelic Care with Experience & Integrity
At the Psychedelic Science Institute (PSI) and our affiliated TRIP Clinics, we believe psychedelic-assisted therapy and psychedelic medicines hold transformative potential for mental health care and neuroscience. But despite growing interest, much more rigorous research is needed to determine which medicines are safe and effective for which conditions and populations. In this evolving field—one with both a rich history and significant recent hype—credible, experienced, and compassionate clinician-scientists are essential.
We recognize that many people seeking mental health care feel disillusioned by traditional treatment options and overwhelmed by a landscape of conflicting information. At PSI, our team is committed to merging deep clinical experience with scientific innovation, creating a space where science, safety, and support meet real people.
PSI emerged from the unification of two pioneering organizations in Southern California:
- The Pacific Neuroscience Institute’s Treatment & Research In Psychedelics (TRIP) Center, launched in Santa Monica in 2019. PNI has a decade-long record of delivering cutting-edge neuroscience and mental health care, including extensive experience conducting clinical trials across 10 Centers of Excellence.
- The California Center for Psychedelic Therapy (CCPT), established in Larchmont in 2018. CCPT was the first center in Southern California to offer psychedelic-assisted psychotherapy under the care of licensed psychiatrists and board-registered mental health professionals. It is also the region’s longest-standing provider of ketamine-assisted psychotherapy.
- Our founders, Daniel Kelly, MD, Keith Heinzerling, MD, Brooke Balliett, LMFT, Micah Linton, PsyD, and Greg Kearns, MBA, are internationally recognized leaders in clinical neuroscience, mental health, psychedelic-assisted therapy, and healthcare strategy.
- In 2025, with support from the nonprofit Psychedelic Innovation Fund, the teams at TRIP and CCPT came together to form PSI. Through this merger, we are building a new, sustainable model of mental health care grounded in research, compassion, and real-world impact.
PSI and TRIP Clinics are dedicated to:
- Developing safe and effective psychedelic-assisted therapies for conditions including anxiety, depression, addiction, PTSD, bipolar disorder, and other behavioral health challenges.
- Advancing psychedelic science and understanding the neuroplastogenic potential of psychedelic medicines to change behavior, improve brain health, and optimize quality of life.
- Expanding access to psychedelic-assisted therapies for all those in need, including underserved and under-represented communities. We are proud to be an LGBTQIA+ and BIPOC-affirming practice, committed to inclusive care that helps patients and communities thrive. We don't just talk access, we deliver it.
- Educating the medical community and public on the impact of psychedelic-assisted therapies and the evolving field of psychedelic science.
Structured, Human, and Safe Care
At PSI, we are not just offering psychedelic therapy; we are helping define its future. Our dual-path model integrates real-world clinical care with rigorous clinical research to help shape the next decade of psychedelic medicine.
A structured, supervised program for those facing depression, trauma, or chronic pain, led by clinicians with decades of experience in ketamine therapy.
Join a trial and help move psychedelic medicine forward. Our research spans conditions like treatment-resistant depression and PTSD. All trials are medically supervised and patient-centered.
What Sets Us Apart:
Credibility
Our care is delivered by a highly experienced, compassionate team of licensed therapists and physicians who follow clear protocols to ensure safety and build trust.
Patient-Centricity
Patients remain in control with full understanding, consent and freedom to pause or opt out at any time. We emphasize preparation, supervised dosing, and post-session integration within a “set and setting” model.
Clarity
We communicate clearly, offering facts, education, and support to help patients understand options and form realistic expectations.
Diversity
As one of the most active psychedelic trial and treatment sites in the US, we understand the importance of inclusion of all identities in our work. We are honored to serve a diverse population of participants, including members of the BIPOC and LGBTQIA+ communities.
Take the Next Step
You don’t have to have it all figured out.
Discover our medically supervised care options.
See what care is right for you.